Trodelvy™ (sacituzumab govitecan-hziy) – Indication withdrawal
October 18, 2024 - Gilead announced plans to voluntarily withdraw the accelerated approval for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Top